tallózása szerző szerint "Miklya, Ildikó"

1-8 / 8

A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain

Knoll, József; Baghy, Kornélia; Eckhardt S; Ferdinandy, Péter; Garami, Miklós; Hársing, László Gábor; Hauser, Péter; Mervai, Zsolt; Pócza, Tímea; Schaff, Zsuzsa; Schuler, Dezső; Miklya, Ildikó (2017)

AIMS: First proof to show that (-)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first beta-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) ...
A parkin szerepe a Parkinson-kórban

Miklya, Ildikó; Goltl P; Hafenscher F; Pencz N (2014)

Parkin (Parkinson juvenile disease protein 2) is a ~52 kDa (426 amino acid) enzyme protein, encoded by PARK2 gene and located on the 6q chromosome. It plays an important role in the ubiquitin-proteasome system and acts ...
Az alpha-szinuklein szerepe Parkinson-kórban

Miklya, Ildikó; Pencz N; Hafenscher F; Goltl P (2014)

alpha-synuclein, a small protein (140 amino acids) encoded by the SNCA gene is the best known isoform of the synuclein protein family. Though its physiological role is still not fully clarified, there is growing experimental ...
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline

Miklya, Ildikó (2014)

Background (-)-Deprenyl and rasagiline are classified as selective inhibitors of B-type MAO. The DATATOP study revealed that the administration of (-)-deprenyl to untreated patients with Parkinson's disease (PD) significantly ...
Geroprotection in the future. In memoriam of Joseph Knoll

Ferdinandy, Péter; Yoneda, Fumio; Muraoka, Shizuko; Fürst, Zsuzsanna; Gyires, Klára; Miklya, Ildikó (2020)

In memoriam of Joseph Knoll: the selegiline story continues.
Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)

Knoll, József; Miklya, Ildikó (2016)

AIMS: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (-)-deprenyl (0.25mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated ...
Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response

Knoll, József; Zelena, Dóra; Timár, Júlia; Baghy, Kornélia; Mervai, Zsolt; Miklya, Ildikó (2020)
The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)

Miklya, Ildikó (2016)

Deprenyl/Selegiline (DEP), created by Joseph Knoll in the 1960s, registered in more than 60 countries to treat Parkinson’s disease, Alzheimer’s disease, major depressive disorder; and used as an anti-aging drug, achieved ...

1-8 / 8

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban

Hozzáférésem

Bejelentkezés

tallózása szerző szerint "Miklya, Ildikó"

DSpace/Manakin Repository

tallózása szerző szerint "Miklya, Ildikó"

Keresés

Tallózás

Teljes repozitórumban

Hozzáférésem